Ocugen’s OCU410 Shows Promise in Geographic Atrophy

Ocugen reported positive Phase II results for its AAV gene therapy OCU410 in geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD) from the ArMaDa trial (NCT06018558).

Preliminary 12-month data showed 46% reduction in macular lesion growth across medium and high dose groups versus placebo. The medium dose cohort saw a 54% reduction, while the high dose group had 36% less lesion growth. Half of treated patients achieved >50% lesion size reduction, which were described as “robust anatomic efficacy.” No serious treatment-emergent adverse events (TEAEs) were reported.

OCU410 is advancing to Phase III in 2026, with full Phase II data expected in Q1. The results are notable as no approved therapies exist for GA in Europe, and only two are approved in the US (Syfovre and Iservay). Other late-stage competitors include tinlarebant, AVD-104, and BI 1584862.

The global AMD market is projected to reach $20.5bn across the 7MM by 2034.

21-01-2026